Puma Biotechnology (PBYI) Receivables - Other (2012 - 2019)

Puma Biotechnology (PBYI) posted Receivables - Other of $9.9 million for Q1 2019, up 743.57% on a QoQ basis from $1.2 million in Q4 2018.

Puma Biotechnology (PBYI) Receivables - Other (2012 - 2019) Analysis & Trends

Puma Biotechnology's Receivables - Other history runs 5 years deep, the most recent figure standing at $9.9 million for Q1 2019.

Quarterly Receivables - Other changed N/A year-over-year to $9.9 million in Q1 2019, while the trailing twelve-month figure through Mar 2019 was $9.9 million (changed N/A YoY) and the FY2018 annual result came in at $1.2 million, changed N/A from the prior year.
Receivables - Other was $9.9 million for Q1 2019 at Puma Biotechnology, up from $1.2 million in the prior quarter.
Across five years, Receivables - Other topped out at $11.2 million in Q3 2018 and bottomed at $1.2 million in Q4 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Puma Biotechnology	407.27 Mn	368.99 Mn	34.39 Mn

Download Data